PT Tofflon Science And Technology Indonesia

PT. Tofflon Science and Technology Indonesia is Tofflon Science and Technology Group Co. Ltd.’s Indonesia Subdiory. Tofflon Science and Technology Group Co. Ltd.(Short for “Tofflon”, Stock Code: SZ 300171) was founded in 1993. It is a comprehensive pharmaceutical equipmentsupplier to provide process support, core equipments, integrated system and pharma engineering for thepharma and biotech industry in theworld. Since its foundation, Tofflon has supplied more than 800 equipments and systems for 200 pharmaceutical companies across over 40 countries and regions in theworld which have been widely applied in the fields of liquid and Lyo injectables, chemicalAPI, bioengineeringand pharma packaging, etc.

Tofflon focuses on studying drug manufacture science and process equipment manufacture science,practicesdrug process knowledge integration with pharma equipment knowledge. Taking“Synergy Global AdvancedTechnologies”strategy, Tofflon builds comprehensivedevelopmentinstitute in Shanghai headquarters, is buildingdesignhouses and technical canter in USA, Europe and India, establishes joint ventures and technology collaboration with the technical partners from USA, Europe and Japan. Furthermore Tofflon has built five modern pharmaceutical equipment manufacturing bases with global competitiveness.It can provide competitive pharmaceuticalequipmentand system solutionsvaluablefor today and future’s competence improvement of the pharma and biotech companies.

Tocommitto its mission“Expertise in Pharmaceutical Industry”, Tofflon will continuously work with pharmaceutical industry to face and meetthechallenges andpressuresin theindustrythrough developing“innovative drug manufacturing science”and building“advanced drug manufacturing platform”. In thefollowingyears, Tofflon will dedicate itself to grow from“China Tofflon to Global Tofflon”, from“Equipment Supplier to Solution Provider”so as to grow up to a totalsolutionproviderof pharmaceutical manufacturing systems and engineering for the global pharma and biotechindustrytocontributetothemaximum benefits and welfare of its servedsociety, customers, stockholders, employees and their families.